Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-TLR9 intrabody
- Development stage
- Preclinical
- Lead developer
- Helmholtz Centre for Infection Research
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intratumoral
01
Overview
The anti-TLR9 intrabody (αT9ib) is an experimental biologic consisting of a single-chain variable fragment (scFv) derived from the monoclonal antibody clone 5G5. It is designed to be expressed intracellularly and localized to the endoplasmic reticulum (ER). Its mechanism involves binding to Toll-like receptor 9 (TLR9) within the ER, thereby preventing the receptor's translocation to endolysosomal compartments where it would normally encounter its ligands (unmethylated CpG DNA). By sequestering TLR9, the intrabody inhibits downstream signaling pathways, including NF-κB activation and the production of pro-inflammatory cytokines like TNFα. This approach is being investigated for the treatment of autoimmune diseases and pancreatic ductal adenocarcinoma (PDAC), where TLR9 signaling contributes to chronic inflammation and tumor progression.
- Other names
- anti-TLR9 scFv intrabodyanti-TLR-9 scFv intrabodyanti-TLR 9 scFv intrabodyTLR9 intrabodyTLR-9 intrabodyTLR 9 intrabody
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on anti-TLR9 intrabody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-TLR9 intrabody.